GlassScriptPhysician profile
Pamela M Persak
NPI 1437133766
$553.96
in general payments reported to CMS, 2019-2025
13 companies · $80.21 in 2025
The $80.21 reported for 2025 was less than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $130 · 2020: $12.42 · 2022: $13.00 · 2023: $123 · 2024: $196 · 2025: $80.21.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $399.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $398.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $146.40 | 2022-2025 | Qelbree, Qelbree |
| Ironshore Pharmaceuticals INC. | $90.38 | 2019-2024 | Jornay Pm |
| Cranial Technologies, INC | $67.67 | 2023-2025 | Doc Band |
| Pfizer INC. | $63.46 | 2019-2024 | |
| Kaleo, INC. | $30.40 | 2019-2023 | Auvi-Q |
| Corium, LLC | $27.88 | 2025 | Azstarys |
| Verrica Pharmaceuticals INC. | $26.25 | 2024 | Ycanth |
| Sanofi-Aventis U.S. LLC | $23.14 | 2024 | |
| Phadia US INC. | $17.97 | 2023 | Immunocap |
| Rhodes Pharmaceuticals L.P. | $17.19 | 2019 | |
| Dermira, INC. | $15.47 | 2019 | |
| Neos Therapeutics, LP | $15.33 | 2019 | |
| Genentech USA, INC. | $12.42 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pamela Persak listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.